RESUMEN
Myasthenia gravis is an autoimmune disorder where antibodies against the nicotinic Ach receptor resulting in impaired transmission at the NM junction. A number of drugs have been reported to cause neuromuscular blockade and/or to increase weakness in myasthenia gravis. We report a case of myasthenia gravis in which the calcium channel blocker-nifedipine caused the worsening of the symptoms.
Asunto(s)
Adulto , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Bloqueadores de los Canales de Calcio/efectos adversos , Humanos , Masculino , Miastenia Gravis/tratamiento farmacológico , Nifedipino/efectos adversosRESUMEN
A 30 year old male presented with crossed buccofacial apraxia, apraxia for speech, Left UMN facial palsy and hemiplegia following scorpion sting. A cerebrovascular accident can develop following a scorpion sting due to venom-induced cerebral thrombosis.
Asunto(s)
Adulto , Animales , Picaduras de Arañas/complicaciones , Trastornos Cerebrovasculares/etiología , Parálisis Facial/etiología , Hemiplejía/etiología , Humanos , Masculino , EscorpionesRESUMEN
870 household contacts of leprosy patients were examined for sub-clinical infection with M. leprae by smear (skin and nasal), lepromin and FLA-ABS tests. 0.6%, 3.3%, 71.5% and 14.4% of the contacts were found to be positive for skin smear, nasal smear, lepromin and FLA-ABS tests respectively. An analysis of the results revealed that 4% of the lepromin positive contacts and 3.6% of the lepromin negative contacts were positive to both FLA-ABS and skin or nasal smear.
Asunto(s)
Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Vivienda , Humanos , Lactante , Lepromina/diagnóstico , Lepra/microbiología , Masculino , Persona de Mediana Edad , Mycobacterium leprae/aislamiento & purificación , Piel/microbiologíaRESUMEN
Serum beta-glucuronidase activity was estimated using phenolphthalein mono-beta-glucuronic acid as substrate in 176 individuals including 72 lepromatous leprosy patients, 24 patients of borderline leprosy, 42 of borderline tuberculoid and 38 healthy controls. Of these, 35 patients (20 with lepromatous leprosy, 5 with borderline leprosy and 10 with borderline tuberculoid) were untreated. The enzyme levels were increased significantly in all types of leprosy, the highest levels being seen in treated lepromatous leprosy patients (105.0 SU). There was also a significant difference in the enzyme activity between untreated patients and those on combined dapsone and rifampicin therapy, in all three types of leprosy. Among untreated patients, the maximum value observed in lepromatous leprosy was 93.4 SU. The lowest enzyme level in healthy control was 19.5 SU and the maximum was 54.0 SU. The results suggest that in leprosy patients, especially in those on daily multidrug regimens, there is an extensive damage of leucocytes and liver cells where the enzyme is largely present.